A randomised study of TURP after intraprostatic injection of mepicacaine/adrenaline versus regular TURP in patients with LUTS/BPO
DOI:
https://doi.org/10.2340/sju.v58.7798Keywords:
TURP, intraprostatic injection, mepivacaine/adrenalineAbstract
Introduction: During transurethral resection of the prostate (TURP), the most established surgical treatment of lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO), the prostate can bleed profusely, bringing about anaemia and compromised oxygen delivery to the entire body.
Objective: The primary objective of this study was to assess the efficacy of mepivacaine and adrenaline (MA) injected into the prostate on bleeding. The primary endpoint was to measure blood loss per resected weight of prostate tissue.
Material and methods: This randomised controlled trial evaluated 81 patients with LUTS/BPO. Patients were randomly allocated to regular TURP or TURP with intraprostatic injections of MA.
Results: On univariable analyses there was a significant difference in resection weight in favour of the experimental group, not reflected by a statistically significant difference in the other studied outcome parameters. Nevertheless, in multivariable analyses, blood loss per resection weight, which was the primary outcome, showed a significant decrease in favour of the experimental group. Clavien–Dindo complication classification showed three men with a grade I complication and two men with grade II.
Conclusions: The results obtained in this study showed that it is beneficial to apply intraprostatic injections of MA in immediate conjunction with TURP, in terms of blood loss per resected gram. The study is, however, small and corroboration of our results in more extensive prospective studies may therefore be warranted before embarking upon this technique.
Downloads
References
Foster HE, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol. 2018;200(3):612–19. https://doi.org/10.1016/j.juro.2018.05.048 DOI: https://doi.org/10.1016/j.juro.2018.05.048
Parsons JK, Dahm P, Kohler TS, Lerner LB, Wilt TJ. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2020. J Urol. 2020;204(4):799–804. https://doi.org/10.1097/JU.0000000000001298 DOI: https://doi.org/10.1097/JU.0000000000001298
Cornu J-NL, Gravas S, Gacci M, Hashim H, Herrmann TRW, Netsch C, et al. Management of non-neurogenic male LUTS. 2020. Available from: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts [cited 27 March 2020].
Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180(1):246–9. https://doi.org/10.1016/j.juro.2008.03.058 DOI: https://doi.org/10.1016/j.juro.2008.03.058
Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol. 2015;67(6):1066–96. https://doi.org/10.1016/j.eururo.2014.06.017 DOI: https://doi.org/10.1016/j.eururo.2014.06.017
Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP) – incidence, management, and prevention. Eur Urol. 2006;50(5):969–79; discussion 980. https://doi.org/10.1016/j.eururo.2005.12.042 DOI: https://doi.org/10.1016/j.eururo.2005.12.042
Hawary A, Mukhtar K, Sinclair A, Pearce I. Transurethral resection of the prostate syndrome: almost gone but not forgotten. J Endourol. 2009;23(12):2013–20. https://doi.org/10.1089/end.2009.0129 DOI: https://doi.org/10.1089/end.2009.0129
Stucki P, Marini L, Mattei A, Xafis K, Boldini M, Danuser H. Bipolar versus monopolar transurethral resection of the prostate: a prospective randomized trial focusing on bleeding complications. J Urol. 2015;193(4):1371–5. https://doi.org/10.1016/j.juro.2014.08.137 DOI: https://doi.org/10.1016/j.juro.2014.08.137
Fagerstrom T, Nyman CR, Hahn RG. Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique: a single-centre randomized trial of 202 patients. BJU Int. 2010;105(11):1560–4. https://doi.org/10.1111/j.1464-410X.2009.09052.x DOI: https://doi.org/10.1111/j.1464-410X.2009.09052.x
Fagerstrom T, Nyman CR, Hahn RG. Complications and clinical outcome 18 months after bipolar and monopolar transurethral resection of the prostate. J Endourol. 2011;25(6):1043–9. https://doi.org/10.1089/end.2010.0714 DOI: https://doi.org/10.1089/end.2010.0714
Schelin S, Claezon A, Sundin A, Wagrell L. Effects of intraprostatic and periprostatic injections of mepivacaine epinephrine on intraprostatic blood flow during transurethral microwave thermotherapy: correlation with [15O]H2O-PET. J Endourol. 2004;18(10):965–70. https://doi.org/10.1089/end.2004.18.965 DOI: https://doi.org/10.1089/end.2004.18.965
Schelin S. Mediating transurethral microwave thermotherapy by intraprostatic and periprostatic injections of mepivacaine epinephrine: effects on treatment time, energy consumption, and patient comfort. J Endourol. 2002;16(2):117–21. https://doi.org/10.1089/089277902753619645 DOI: https://doi.org/10.1089/089277902753619645
Knutson T, Johansson A, Damber JE, Fall M, Vesely S, Peeker R. Intraurethral prostate injections with mepivacaine epinephrine: effects on patient comfort, treatment time and energy consumption during high-energy transurethral microwave thermotherapy. Scand J Urol Nephrol. 2009;43(4):300–6. https://doi.org/10.1080/00365590903092889 DOI: https://doi.org/10.1080/00365590903092889
Stenmark F, Brudin L, Stranne J, Peeker R. High-energy feedback microwave thermotherapy and intraprostatic injections of mepivacaine and adrenaline: an evaluation of calculated cell kill accuracy and responder rate. Scand J Urol. 2014;48(4):374–8. https://doi.org/10.3109/21681805.2013.879921 DOI: https://doi.org/10.3109/21681805.2013.879921
Schelin S. Transurethral resection of the prostate after intraprostatic injections of mepivacain epinephrine: a preliminary communication. Scand J Urol Nephrol. 2009;43(1):63–7. https://doi.org/10.1080/00365590802465061 DOI: https://doi.org/10.1080/00365590802465061
Sagen E, Namnuan RO, Hedelin H, Nelzén O, Peeker R. The morbidity associated with a TURP procedure in routine clinical practice, as graded by the modified Clavien-Dindo system. Scand J Urol. 2019;53(4):240–5. https://doi.org/10.1080/21681805.2019.1623312 DOI: https://doi.org/10.1080/21681805.2019.1623312
Mamoulakis C, Efthimiou I, Kazoulis S, Christoulakis I, Sofras F. The modified Clavien classification system: a standardized platform for reporting complications in transurethral resection of the prostate. World J Urol. 2011;29(2):205–10. https://doi.org/10.1007/s00345-010-0566-y DOI: https://doi.org/10.1007/s00345-010-0566-y
Crea G, Sanfilippo G, Anastasi G, Magno C, Vizzini C, Inferrera A. Pre-surgical finasteride therapy in patients treated endoscopically for benign prostatic hyperplasia. Urol Int. 2005;74(1):51–3. https://doi.org/10.1159/000082709 DOI: https://doi.org/10.1159/000082709
Donohue JF, Sharma H, Abraham R, Natalwala S, Thomas DR, Foster MC. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. J Urol. 2002;168(5):2024–6. https://doi.org/10.1016/S0022-5347(05)64287-5 DOI: https://doi.org/10.1016/S0022-5347(05)64287-5
Lira-Dale A, Maldonado-Avila M, Gil-Garcia JF, Mues-Guizar EH, Nerubay-Toiber R, Guzmán-Esquivel J, et al. Effect of intraprostatic epinephrine on intraoperative blood loss reduction during transurethral resection of the prostate. Int Urol Nephrol. 2012;44(2):365–9. https://doi.org/1007/s11255-011-0071-2 DOI: https://doi.org/10.1007/s11255-011-0071-2
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Fredrik Stenmark, Lars Brundin, Olof Gunnarsson, Henrik Kjölhede, Edvard Lekås, Ralph Peeker, Marianne Månsson, Jonas Richthoff, Johan Stranne
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Acta Chirurgica Scandinavica Society owns the copyright for all material published until Volume 57 (2023) unless otherwise specified. As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
